Core Points - Hofseth BioCare ASA (HBC) is conducting a private placement of new shares, with the completion of tranche 2 (T2 Offer Shares) contingent upon an extraordinary general meeting (EGM) [1] - The EGM is scheduled for 20 November 2025, and the company has secured voting commitments from shareholders to meet the majority requirement for approval [2] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, converting by-products from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [4] Scientific and Health Benefits - HBC emphasizes scientific evidence in its product development, leading to partnerships and the identification of health benefits, including improved iron metabolism and immune health [5] - The company has secured several patents for its discoveries and has established a biotech subsidiary, AecorBio Inc., focusing on therapeutics for prostate and ovarian cancer, as well as asthma [6] Market Presence - HBC is listed on the Oslo Stock Exchange under the ticker "HBC" [7]

Group 1: Bond Issuance - The company has successfully placed CHF-denominated unsecured bonds totaling approximately CHF 3.5 million, subscribed by investors in Switzerland and Liechtenstein [2] - The settlement of the bond issue is expected to occur on 5 May 2025, and the bonds will not be listed on any stock exchange or trading venue [2] - The bonds have a term of three years, maturing on 30 April 2028, with an interest rate of 10% per annum and quarterly interest payments starting on 30 September 2025 [3] Group 2: Corporate Purpose and Financial Details - The net proceeds from the bond issuance will be used for general corporate purposes [2] - The bonds are callable at par value at quarterly intervals, with the first call option available on 30 June 2026 [3] Group 3: Company Overview - Hofseth BioCare ASA is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [3] - The company upcycles side streams of the salmon industry into health-improving ingredients such as ProGo®, OmeGo®, and CalGo® / NT-II((TM)) [3][4] - Hofseth BioCare emphasizes scientific evidence and has established academic partnerships to identify unique health benefits, including improved iron metabolism and immune health [4] Group 4: Research and Development - The company has received patents for its discoveries and has spun out a biotech-focused company, HBC Immunology, which is developing therapeutics for prostate and ovarian cancer, as well as a therapy for asthma [4]